Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Clinical trial NCT02275416 · COMPLETED
Trial details
- NCT number
- NCT02275416
- Sponsor
- Ultimovacs ASA
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-02
- Primary completion
- 2016-10-06
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.